Serum CX3CL1/fractalkine concentrations are positively associated with disease severity in postmenopausal osteoporotic patients.

CONCLUSIONS: Serum FKN may serve as a novel biomarker for assessing disease progression and a new potential therapeutic target for anti-resorptive treatment in osteoporosis patients. PMID: 27476376 [PubMed - as supplied by publisher]
Source: British Journal of Biomedical Science - Category: Laboratory Medicine Tags: Br J Biomed Sci Source Type: research